- Home
- GNLX vs SPRO Comparison
GNLX vs SPRO Comparison
Compare GNLX & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- SPRO
- Stock Information
- Founded
- GNLX 2001
- SPRO 2013
- Country
- GNLX United States
- SPRO United States
- Employees
- GNLX N/A
- SPRO N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- SPRO Health Care
- Exchange
- GNLX Nasdaq
- SPRO Nasdaq
- Market Cap
- GNLX 73.2M
- SPRO 74.0M
- IPO Year
- GNLX 2023
- SPRO 2017
- Fundamental
- Price
- GNLX $2.96
- SPRO $1.32
- Analyst Decision
- GNLX Strong Buy
- SPRO Strong Buy
- Analyst Count
- GNLX 4
- SPRO 3
- Target Price
- GNLX $26.75
- SPRO $7.00
- AVG Volume (30 Days)
- GNLX 166.7K
- SPRO 124.2K
- Earning Date
- GNLX 08-14-2024
- SPRO 08-05-2024
- Dividend Yield
- GNLX N/A
- SPRO N/A
- EPS Growth
- GNLX N/A
- SPRO N/A
- EPS
- GNLX N/A
- SPRO 0.33
- Revenue
- GNLX $8,000.00
- SPRO $118,459,000.00
- Revenue This Year
- GNLX N/A
- SPRO N/A
- Revenue Next Year
- GNLX N/A
- SPRO N/A
- P/E Ratio
- GNLX N/A
- SPRO $4.04
- Revenue Growth
- GNLX N/A
- SPRO 118.43
- 52 Week Low
- GNLX $1.60
- SPRO $0.99
- 52 Week High
- GNLX $30.44
- SPRO $1.89
- Technical
- Relative Strength Index (RSI)
- GNLX 67.91
- SPRO 47.38
- Support Level
- GNLX $1.99
- SPRO $1.30
- Resistance Level
- GNLX $2.97
- SPRO $1.37
- Average True Range (ATR)
- GNLX 0.24
- SPRO 0.08
- MACD
- GNLX 0.09
- SPRO 0.00
- Stochastic Oscillator
- GNLX 84.31
- SPRO 51.56
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.